Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lawrence Corey

Showing results (451-460 of 551) with videos related to

Pageof 56
Sort By:
NPJ Vaccines|January 17, 2026
Association between COVID-19 vaccine efficacy and epidemic force of infectionJing Xu, M Elizabeth Halloran, Mia Moore, et al.
The Journal of Infectious Diseases|February 16, 2017
Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy TrialHolly E Janes, Kristen W Cohen, Nicole Frahm, et al.
PLOS Global Public Health|April 11, 2025
ALVAC-prime and monomeric gp120 protein boost induces distinct HIV-1 specific humoral and cellular responses compared with adenovirus-prime and trimeric gp140 protein boostLeigh H Fisher, Erica Lazarus, Chenchen Yu, et al.
JAMA Network Open|January 23, 2023
Rapid Development of an Integrated Network Infrastructure to Conduct Phase 3 COVID-19 Vaccine TrialsAlfredo J Mena Lora, Jessica E Long, Yunda Huang, et al.
Plos One|May 12, 2017
Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative womenPeter B Gilbert, Jean-Louis Excler, Georgia D Tomaras, et al.
Annals of Internal Medicine|October 22, 2020
Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine TrialsDevan V Mehrotra, Holly E Janes, Thomas R Fleming, et al.
Communications Medicine|April 24, 2025
Distinct immune responses in people living with HIV following SARS-CoV-2 recoveryDieter Mielke, Shuying Sue Li, Daniel J Schuster, et al.
Vaccines|April 23, 2025
Computationally Selected Multivalent HIV-1 Subtype C Vaccine Protects Against Heterologous SHIV ChallengeDieter Mielke, Marina Tuyishime, Natasha S Kelkar, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 25, 2024
Safety and Immunogenicity of a DNA Vaccine With Subtype C gp120 Protein Adjuvanted With MF59 or AS01B: A Phase 1/2a HIV-1 Vaccine TrialNigel Garrett, One Dintwe, Cynthia L Monaco, et al.
The Lancet. HIV|May 1, 2024
Safety and immunogenicity of a polyvalent DNA-protein HIV vaccine with matched Env immunogens delivered as a prime-boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a phase 1, placebo-controlled, double-blind randomised controlled trialIan Frank, Shuying S Li, Nicole Grunenberg, et al.
Pageof 56

Showing results (451-460 of 551) with videos related to

Sort By:
Pageof 56
NPJ Vaccines|January 17, 2026
Association between COVID-19 vaccine efficacy and epidemic force of infectionJing Xu, M Elizabeth Halloran, Mia Moore, et al.
The Journal of Infectious Diseases|February 16, 2017
Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy TrialHolly E Janes, Kristen W Cohen, Nicole Frahm, et al.
PLOS Global Public Health|April 11, 2025
ALVAC-prime and monomeric gp120 protein boost induces distinct HIV-1 specific humoral and cellular responses compared with adenovirus-prime and trimeric gp140 protein boostLeigh H Fisher, Erica Lazarus, Chenchen Yu, et al.
JAMA Network Open|January 23, 2023
Rapid Development of an Integrated Network Infrastructure to Conduct Phase 3 COVID-19 Vaccine TrialsAlfredo J Mena Lora, Jessica E Long, Yunda Huang, et al.
Plos One|May 12, 2017
Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative womenPeter B Gilbert, Jean-Louis Excler, Georgia D Tomaras, et al.
Annals of Internal Medicine|October 22, 2020
Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine TrialsDevan V Mehrotra, Holly E Janes, Thomas R Fleming, et al.
Communications Medicine|April 24, 2025
Distinct immune responses in people living with HIV following SARS-CoV-2 recoveryDieter Mielke, Shuying Sue Li, Daniel J Schuster, et al.
Vaccines|April 23, 2025
Computationally Selected Multivalent HIV-1 Subtype C Vaccine Protects Against Heterologous SHIV ChallengeDieter Mielke, Marina Tuyishime, Natasha S Kelkar, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 25, 2024
Safety and Immunogenicity of a DNA Vaccine With Subtype C gp120 Protein Adjuvanted With MF59 or AS01B: A Phase 1/2a HIV-1 Vaccine TrialNigel Garrett, One Dintwe, Cynthia L Monaco, et al.
The Lancet. HIV|May 1, 2024
Safety and immunogenicity of a polyvalent DNA-protein HIV vaccine with matched Env immunogens delivered as a prime-boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a phase 1, placebo-controlled, double-blind randomised controlled trialIan Frank, Shuying S Li, Nicole Grunenberg, et al.
Pageof 56